<?xml version='1.0' encoding='utf-8'?>
<document id="28237536"><sentence text="Early Experience of Macitentan for Pulmonary Arterial Hypertension in Adult Congenital Heart Disease."><entity charOffset="20-30" id="DDI-PubMed.28237536.s1.e0" text="Macitentan" /></sentence><sentence text="Endothelin receptor antagonists (ERA) have been recognised as effective therapy for pulmonary arterial hypertension in congenital heart disease (CHD-PH), and Eisenmenger syndrome (ES) since The Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (Breathe 5) study" /><sentence text=" A new dual receptor antagonist - Macitentan - is currently undergoing trials to determine its efficacy in simple ES"><entity charOffset="34-44" id="DDI-PubMed.28237536.s3.e0" text="Macitentan" /></sentence><sentence text=" To date there is little information on this therapy in CHD and we report our first experience, some with more complex diseases" /><sentence text="" /><sentence text="Data was collected prospectively from September 2014" /><sentence text=" Patients with CHD-PH were started on or converted to macitentan if they required therapy with phosphodiesterase 5 inhibitor (PDE5i) or if there was insufficient response or a reaction to bosentan, especially those with trisomy 21"><entity charOffset="15-21" id="DDI-PubMed.28237536.s7.e0" text="CHD-PH" /><entity charOffset="54-64" id="DDI-PubMed.28237536.s7.e1" text="macitentan" /><entity charOffset="188-196" id="DDI-PubMed.28237536.s7.e2" text="bosentan" /><pair ddi="false" e1="DDI-PubMed.28237536.s7.e0" e2="DDI-PubMed.28237536.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28237536.s7.e0" e2="DDI-PubMed.28237536.s7.e1" /><pair ddi="false" e1="DDI-PubMed.28237536.s7.e0" e2="DDI-PubMed.28237536.s7.e2" /><pair ddi="false" e1="DDI-PubMed.28237536.s7.e1" e2="DDI-PubMed.28237536.s7.e1" /><pair ddi="false" e1="DDI-PubMed.28237536.s7.e1" e2="DDI-PubMed.28237536.s7.e2" /></sentence><sentence text=" Patients were seen approximately three months after starting therapy to assess echocardiography, six minute walk test, clinical response and tolerability" /><sentence text=" All patients underwent monthly liver tests initially, but this was reduced to three-monthly in Q4 2015" /><sentence text="" /><sentence text="Fifteen patients with CHD-PH (eight male, seven female) were started on macitentan, median (range) age 38 (23-61) years, and eight patients with Down's syndrome"><entity charOffset="22-28" id="DDI-PubMed.28237536.s11.e0" text="CHD-PH" /><entity charOffset="72-82" id="DDI-PubMed.28237536.s11.e1" text="macitentan" /><pair ddi="false" e1="DDI-PubMed.28237536.s11.e0" e2="DDI-PubMed.28237536.s11.e0" /><pair ddi="false" e1="DDI-PubMed.28237536.s11.e0" e2="DDI-PubMed.28237536.s11.e1" /></sentence><sentence text=" Eight patients had complex CHD with one having unoperated double inlet left ventricle with ventriculo-arterial discordance, one had double outlet right ventricle and six with complete atrio-ventricular septal defect" /><sentence text=" Six patients were ERA naïve and nine patients changed from bosentan to macitentan in order to achieve improved drug-drug interaction"><entity charOffset="60-68" id="DDI-PubMed.28237536.s13.e0" text="bosentan" /><entity charOffset="72-82" id="DDI-PubMed.28237536.s13.e1" text="macitentan" /><pair ddi="false" e1="DDI-PubMed.28237536.s13.e0" e2="DDI-PubMed.28237536.s13.e0" /><pair ddi="false" e1="DDI-PubMed.28237536.s13.e0" e2="DDI-PubMed.28237536.s13.e1" /></sentence><sentence text=" Median length of time of treatment with macitentan is 289 (0-694) days to date"><entity charOffset="41-51" id="DDI-PubMed.28237536.s14.e0" text="macitentan" /></sentence><sentence text=" One discontinued due to rash and feeling unwell; one was unable to comply with medication due to learning difficulties and one died soon after commencing rescue therapy" /><sentence text=" This last patient was functional class IV with oxygen saturation of 67% at rest, with right heart failure and was unable to perform a walk test before commencing therapy"><entity charOffset="48-54" id="DDI-PubMed.28237536.s16.e0" text="oxygen" /></sentence><sentence text=" All patients who remained on therapy had significant increase in six minute walk test from median 286 (120-426) to 360m (150-450)(p &lt;0" /><sentence text="05), most notably in those treatment naïve" /><sentence text=" Functional class median remained at 3 but the range was reduced (1-3)" /><sentence text=" Resting oxygen saturations improved from median 83 range (77-95%) at rest to 91 (77-96%) and at end walk from 78 (48-90%) to 79 (62-96%)"><entity charOffset="9-15" id="DDI-PubMed.28237536.s20.e0" text="oxygen" /></sentence><sentence text=" Tricuspid regurgitant peak Doppler derived pressure drop did not change (as expected) at 4" /><sentence text="6 (4" /><sentence text="3-5" /><sentence text="5)m/s" /><sentence text=" There were no episodes of liver dysfunction" /><sentence text="" /><sentence text="The introduction of this new therapy has been simple and mostly well tolerated in our sick group of patients" /><sentence text=" With the usual reservations concerning the open-label nature of our observations, macitentan has good signals regarding oxygen saturations and encouraging signals relating to efficacy"><entity charOffset="83-93" id="DDI-PubMed.28237536.s28.e0" text="macitentan" /><entity charOffset="121-127" id="DDI-PubMed.28237536.s28.e1" text="oxygen" /><pair ddi="false" e1="DDI-PubMed.28237536.s28.e0" e2="DDI-PubMed.28237536.s28.e0" /><pair ddi="false" e1="DDI-PubMed.28237536.s28.e0" e2="DDI-PubMed.28237536.s28.e1" /></sentence><sentence text="" /></document>